

8 May 2019

ASX ANNOUNCEMENT

FACILITY AGREEMENT SIGNED WITH SIO PARTNERS, LP

Medical technology company Admedus Ltd (**ASX: AHZ**) confirms that it has entered into a facility agreement with SIO Partners, LP (**SIO**) for a secured debt facility of A\$1 million (the **SIO Facility**).

The key terms of the SIO Facility are:

- 18-month term
- 12% interest rate compounding monthly
- one-off A\$125,000 facility fee, which will be capitalised to the loan
- interest and facility fee to be capitalised to the loan balance and repayable at maturity
- if Admedus launches a rights issue while the loan is outstanding, SIO may elect to offset all or part of the outstanding balance against its entitlement and any underwriting commitment
- if shareholder approval is obtained, the outstanding balance may at SIO's election by notice provided to AHZ no later than 3 months prior to maturity be converted to ordinary shares in AHZ at the lesser of:
 - A\$0.02 per share; and
 - 80% of the volume weighted average market price for ordinary shares calculated over 5 trading days immediately before the date on which the shares are to be issued
- the security granted for the loan is limited to an amount equivalent to A\$1 million

The proceeds of the SIO Facility will provide funds for Admedus to fund general working capital and operational costs. In addition, the Company will continue with the restructure of the business' operations to reduce certain overhead costs, and a proposed divestment of the infusion business so as to capitalise on its growing ADAPT® business.

The Company remains in voluntary suspension to facilitate completion of its recapitalisation plan.

ENDS

Admedus Limited


Registered Office:

Suite 302, Level 3, 9 Sherwood Rd, Toowong, Queensland 4066

Customer Service:

T: 1300 550 310 F: 1300 880 398 International: T: +61 (0)7 3152 3200 F: +61 (0)7 3152 3299

E: info@admedus.com W: admedus.com



For more information, please contact:

Admedus@we-buchan.com

About Admedus Limited

Admedus (ASX: AHZ) is a medical technologies company delivering clinically superior solutions that help healthcare professionals create life-changing outcomes for patients. Our focus is on investing in and developing next-generation technologies with world-class partners, acquiring strategic assets to grow product and service offerings, and expanding revenues from our existing medical sales and distribution business. The Company has assets from research & development through clinical development and sales, marketing and distribution.

Website: www.admedus.com

Facebook: www.facebook.com/Admedus

Twitter: @Admedus

